Department of Cardiothoracic Surgery, New York University Langone Health, New York, New York.
Division of Pulmonary and Critical Care Medicine, Department of Medicine, New York University Langone Health, New York, New York.
Ann Thorac Surg. 2021 Feb;111(2):427-435. doi: 10.1016/j.athoracsur.2020.05.108. Epub 2020 Jul 17.
The lung allocation score (LAS) significantly improved outcomes and wait list mortality in lung transplantation. However, mortality remains high for the sickest wait list candidates despite additional changes to allocation distance. Regulatory considerations of overhauling the current lung allocation system have met significant resistance, and changes would require years to implement. This study evaluates whether a modest change to the current system by prioritization of only high-LAS lung transplant candidates would result in lowered wait list mortality.
The Thoracic Simulated Allocation Model was used to evaluate all lung transplant candidates and donor lungs recovered between July 1, 2009 and June 30, 2011. Current lung allocation rules (initial offer within a 250-nautical mile radius for ABO-identical then compatible offers) were run. Allocation was then changed for only patients with an LAS of50 or higher (high-LAS) to be prioritized within a 500-nautical mile radius with no stratification between ABO-identical and compatible offers. Ten iterations of each model were run. Primary end points were wait list mortality and posttransplant 1-year survival.
A total of 6538 wait list candidates and transplant recipients were evaluated per iteration, for a total of 130,760 simulated patients. Compared with current allocation, the adjusted model had a 23.3% decrease in wait list mortality. Posttransplant 1-year survival was minimally affected.
Without overhauling the entire system, simple prioritization changes to the allocation system for high-LAS candidates may lead to decreased wait list mortality and increased organ use. Importantly, these changes do not appear to lead to clinically significant changes in posttransplant 1-year survival.
肺分配评分(LAS)显著改善了肺移植的结果和等待名单死亡率。然而,尽管对分配距离进行了额外的更改,最病重的等待名单候选人的死亡率仍然很高。全面改革当前肺分配系统的监管考虑因素遇到了重大阻力,而且改变需要数年时间才能实施。本研究评估了仅优先考虑高 LAS 肺移植候选人是否会降低等待名单死亡率。
使用胸腔模拟分配模型评估 2009 年 7 月 1 日至 2011 年 6 月 30 日期间所有肺移植候选人和供体肺。运行当前的肺分配规则(对于 ABO 相同的初始报价,然后是相容的报价,在 250 海里半径内提供)。然后,对于 LAS 为 50 或更高(高 LAS)的患者,仅将其分配优先级放在 500 海里半径内,ABO 相同和相容的报价之间没有分层。对每个模型进行了 10 次迭代。主要终点是等待名单死亡率和移植后 1 年生存率。
每个迭代评估了 6538 名等待名单候选人和移植受者,总共模拟了 130760 名患者。与当前分配相比,调整后的模型等待名单死亡率降低了 23.3%。移植后 1 年生存率受影响最小。
在不彻底改革整个系统的情况下,对高 LAS 候选人分配系统进行简单的优先级更改可能会降低等待名单死亡率并增加器官利用率。重要的是,这些变化似乎不会导致移植后 1 年生存率出现临床意义上的变化。